Nurix Therapeutics Says Sanofi Will End SAR448272 Program

What happened

Nurix Therapeutics said Sanofi will discontinue the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminate the program. Nurix does not expect future development, regulatory or commercial milestone payments or royalties for SAR448272.

Confirmed

Global impact / market context

Ending this program removes a potential future revenue stream for Nurix from Sanofi milestone payments and royalties. That can reduce expected cash coming in over time and may make investors focus more on Nurix's other licensed programs and its own spending plans.

Analyst inference

The news is specific to one early-stage drug program rather than Nurix's whole business. Nurix still can receive milestones and royalties from other Sanofi-licensed programs if Sanofi advances them, so investor attention may shift to progress on those remaining programs.

Analyst inference

What to watch

1. Nurix said it remains eligible for milestones and royalties from other licensed programs under the Sanofi collaboration if Sanofi advances them, so updates on those programs matter. Confirmed
2. Watch whether Nurix announces changes to research spending or staff tied to SAR448272, because ending a program may free up or redirect company resources. Proposed
3. Track Nurix's cash available and spending plans in future updates, since losing expected milestone payments could change how long its current funds last. Analyst inference

Evidence

• Original source link unavailable